Abstract:The motivation for this study was the need for novel diuretics in order to circumvent the side effects associated with long‐term use of conventional diuretics. Urea transporters (UTs) are a family of membrane channel proteins that are specifically permeable to urea and play an important role in intrarenal urea recycling and in urine concentration. Using an erythrocyte osmotic lysis assay, we screened a small‐molecule library for inhibitors of urea transport. A novel class of thienoquinolin UT‐B inhibitors were identified, of which PU‐14 had potent inhibition activity on human, rabbit, rat, and mouse UT‐B. The half‐maximal inhibitory concentration of PU‐14 on rat UT‐B‐mediated urea transport was ~0.8 μmol/l, and it did not affect urea transport in mouse blood cell lacking UT‐B but inhibited UT‐A‐type urea transporters. PU‐14 showed no significant cellular toxicity at concentrations up to its solubility limit of 80 μmol/l. Subcutaneous delivery of PU‐14 (at 12.5, 50, and 100 mg/kg) to rats caused an increase of urine output and a decrease of the urine urea concentration and subsequent osmolality without electrolyte disturbances and liver or renal damages. This suggests that PU‐14 has a diuretic effect by urea‐selective diuresis. Thus, PU‐14 or its analogs might be developed as a new diuretic in diseases associated with water retention without causing electrolyte imbalance. PU‐14 may establish ‘chemical knockout’ animal models to study the physiological functions of UTs. Further studies will be focused on the structural modification and characterization of pharmacokinetics and the absorption, distribution, metabolism, excretion, and toxicity properties of PU‐14.

Discovery of Thienoquinolin Urea Transporter Inhibitors Acts As a Potential Diuretic (LB587)